Geneos Therapeutics
Developer of a neo-antigen based personalized immunotherapy designed to offer cancer treatment.
| Date | Investors | Amount | Round |
|---|---|---|---|
| investor investor | €0.0 | round | |
| investor investor investor | €0.0 | round | |
| investor investor investor investor investor investor | €0.0 | round | |
| investor | €0.0 Valuation: €0.0 | round | |
* | $5.0m Valuation: $85.0m | Series A | |
| Total Funding | 000k | ||
Related Content
Geneos Therapeutics is a biotechnology company focused on developing personalized cancer immunotherapies. The company operates in the biotechnology and pharmaceutical market, serving clients such as research institutions, hospitals, and pharmaceutical companies. Geneos's core product is the GT EPICTM platform, which is designed to enhance the efficiency and effectiveness of clinical trials globally. This platform leverages advanced technologies to create personalized neoantigen-targeting vaccines, aiming to improve patient outcomes in oncology. The business model revolves around partnerships, licensing agreements, and direct sales of their proprietary technologies. Revenue is generated through these collaborations, clinical trial services, and the commercialization of their immunotherapy products.
Keywords: biotechnology, immunotherapy, personalized medicine, clinical trials, oncology, neoantigen vaccines, GT EPICTM, cancer treatment, pharmaceutical partnerships, biotech innovation.